Johnson & Johnson and AbbVie beat Q1 revenue forecasts, lifting full-year outlooks on robust immunology and oncology drug performance.
Johnson & Johnson reported Q1 2026 revenue of $24.06 billion, up 9.9% year-over-year, exceeding expectations. Growth was driven by TREMFYA’s 68.3% surge and DARZALEX’s 22.5% rise to $3.96 billion, prompting the company to raise its FY26 guidance to a midpoint of $100.8 billion.
AbbVie posted Q1 revenue of $15 billion, a 12.4% YoY increase, with Skyrizi reaching $4.48 billion (+30.9%) and Rinvoq at $2.12 billion (+23.3%). The gains offset Humira’s 38.6% decline, despite a $744 million IPR&D charge. Both firms face biosimilar competition but outperformed through divergent strategies.
JNJ is diversifying via a DePuy Synthes spin-off and a $1 billion cell therapy investment, while AbbVie focuses on immunology and obesity treatments with a $1.4 billion North Carolina campus expansion.